ASCO GI 2022 Conference Coverage


 

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Study of T-DXd Monotherapy and Combinations in Advanced /Metastatic HER2+ GC/GEJA: DESTINY-Gastric03

230 views
February 1, 2022
0 Comments
Login to view comments. Click here to Login